Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And I'd like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss the third quarter 2025 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer, Isabel Calafonos, Chief Commercial Officer, and Toby Schilke, Chief Financial Officer. Also joining for the Q&A portion will be Dr. Steve Betts, Founder and Chief Scientific Officer, Dr. Dana Pizzuti, Chief Medical and Development Officer, and Dr. Alan Krasner, Chief Endocrinologist. Please note there's a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Clinetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risk and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. In particular, today we will be reviewing launch progress to date, our commercialization plans, as well as estimates relating to market size, future performance, and other data about the acromegaly market, which are all necessarily subject to a high degree of uncertainty and risk. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Kinetics SEC filings, including its annual report on Fo...